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Abstract
Background:  Premature ventricular and supraventricular complexes (PVC and PsVC) are frequent and often symptomatic. 
The magnesium (Mg) ion plays a role in the physiology of cell membranes and cardiac rhythm.
Objective:We evaluated whether the administration of Mg Pidolate (MgP) in patients with PVC and PsVC is superior to 
placebo (P) in improving symptoms and arrhythmia frequency. 
Methods: Randomized double-blind study with 60 consecutive symptomatic patients with more than 240 PVC or PsVC/h 
on 24-hour Holter monitoring who were selected to receive placebo (P) or MgP. To evaluate symptom improvement, a 
categorical and a specific questionnaire for symptoms related to PVC and PsVC was made. Improvement in premature 
complex density (PCD) per hour was considered significant if percentage reduction was ≥70% after treatment. The 
dose of MgP was 3.0 g/day for 30 days, equivalent to 260mg of Mg element. Any patient had structural heart disease 
or renal failure.
Results: Of the 60 patients, 33 were female (55%). Ages ranged from 16 to 70 years old. In the MgP group, 76.6% of 
patients had a PCD reduction >70%, 10% of them >50% and only 13.4% <50%. In the P group, 40% showed slight 
improvement, <30%, in the PC frequency (p < 0.001). Symptom improvement was achieved in 93.3% of patients in the 
MgP group, compared with only 16.7% in the P group (p < 0.001).
Conclusion: Oral Mg supplementation decreases PCD, resulting in symptom improvement. (Arq Bras Cardiol. 2012; 
[online].ahead print, PP.0-0)
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regulation of nerve and muscle cell permeability7-9, and in 
the ATPase – Na +/K + pump8,9. By acting on the physiology 
of cell membranes, Mg has a special role in cardiac rhythm 
maintenance8,9.
Mg is the second most abundant intracellular cation8,9 
and plays an important role in the activity of many 
coenzymes and ATP-dependent reactions, including 
membrane-dependent energy transport9,10. Less than1% 
of magnesium is found in blood9 and only approximately 
0.3% in serum11,12. Therefore, the intracellular deficiencies 
can be underdiagnosed8.
Lifestyles characterized by stress, low micronutrient 
intake, physical training, sleep deprivation, and the use 
of certain medications (diuretics, aminoglycosides, and 
cyclosporine) may lead to Mg deficiency. This ion is mainly 
found in seeds, nuts, vegetables, and wheat bran. In the 
general population, magnesium deficiency probably occurs 
due to low magnesium dietary intake13,14 ,that needs to 
maintain adequate intracellular values and, in the elderly, 
by decreasing appetite14.    
This study aimed to assess whether oral administration of 
magnesium pidolate (MgP) in patients with PVC or PsVC is 
superior to placebo in improving symptoms and frequency 
of PC, as well as whether symptom improvement is related 
to a significant reduction in arrhythmia frequency.
Introduction 
Premature ventricular and supraventricular complexes 
(PVC and PsVC) are frequent and often symptomatic. 
Their prevalence can occur in up to 50% of the general 
population, especially1. The incidence of this arrhythmia 
increases with age2-4. The studies show that most of these 
patients had <1 PVC per hour, usually monomorphic and 
single forms2,3.
Symptoms related to PVC and PsVC can be very 
troublesome or even disabling. Patients may refer to these 
symptoms as a “skipped beat,” “punch in the chest,” 
palpitations, dyspnea, cough, dizziness, atypical chest 
pain, and near syncope5,6, affecting quality of life. These 
symptoms are usually noticed when the PCD is high. 
Premature complexes are directly related to heart cell 
excitability, which is influenced by electrolyte balance in 
intracellular fluid. The interaction between magnesium 
(Mg) and calcium (Ca) has particular relevance in the 
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Methods
Study Design and Participants
Patients were recruited from the Arrhythmia Unit of the 
Heart Institute (InCor), University of São Paulo Medical School 
and Core Vita Clinics. Patients were eligible if they were 
symptomatic and had more than 240 PVC or PsVC per day 
on 24h  Holter monitoring(or more than 10/hour). Exclusion 
criteria were impaired renal function, structural heart disease 
(except mitral valve prolapse without regurgitation), or the use 
of concomitant drugs. The study was approved by the ethics 
committees of the participating centers in the study with the 
number CAPPesq-0613/10.
Procedures
After providing written informed consent, all trial 
participants were randomly assigned to receive placebo (P) 
or magnesium pidolate (MgP), each administered in a blinded 
manner. All the patients did echocardiogram and none of them 
had structural heart disease or electrolyte disturbances; the 
determination of electrolytes( magnesium, sodium, calcium 
and potassium) and the renal function were normal.
 The dose of the MgP was 3.0 g/day for 30 days, 
which contains 260mg of Mg element. The magnesium, 
sodium, calcium, and potassium serum dosage was taken at 
baseline, at 15 days, and at 30 days after randomization.
Holter
The 24-hour Holter (3 channels) was performed at baseline 
and 30 days after  the medication use. The count of the 
premature complexes was performed following  the  institution 
protocol and the premature complex density (PCD) 
was performed dividing the total number of atrial and 
ventricular extra systoles Holter counted in the number of 
hours of recording.
Outcomes
Follow-up visits occurred at randomization, after 15 days, 
and after 30 days. 
To evaluate symptom improvement, a specif ic 
questionnaire related to PC was made with the following 
questions:1- Failure or “leaps” in the chest ;2-Couch with 
palpitations;3-Dizziness;4-Dyspnea:5-Sudoresis and/or 
chest pain. According to frequency of symptoms was made 
a “score” (Fig. 1). For this “score”, was only considered 
an improvement, if the patient had a reduction of at least 
two categories, for example, was in the score IV  before 
treatment and  migrated to the score I or II after treatment 
.Furthermore, it was made a categorical classification of 
patients with questioning whether there was improvement of 
symptoms, with only answers “yes” or “no “.
 
Statistical Analysis
To  m e e t  t h e  o b j e c t i v e s  o f  t h e  s t u d y,  w e 
calculated the percentage changes in PCD /hour, 
and was considered success criteria, after treatment, 
the percentage reduction   ≥70% per 24-hour Holter.  Data are 
presented using summary statistics (mean, standard deviation, 
median, minimum, maximum). Outcome variables were 
compared between groups using a Mann-Whitney test15. The 
improvement of either PCD or symptoms was described using 
absolute and relative values. The existence of an association 
between groups and the improvement of each criterion was 
performed using Fisher’s exact test15. A p value of 0.05 was 
considered statistically significant. We described the values  of 
magnesium and potassium before medication, and at 15 and 
31 days after medication use, according to groups, and also 
compared the values  between groups and moments using 
analysis of variance with repeated measures and 2 factors16.
A statistical power of 80% was chosen to detect a 60% 
symptom reduction with MgP and 30% with P, with a 
confidence interval of 95%. 
Results
A total of 60 patients were enrolled in the program between 
October 2010 and August 2011. Both treatment groups had 
similar baseline characteristics. The mean age was 46.47 
(MgP) to 48.53 (P), and 55% were women (Table 1). Age 
description and PCD variation according to each group are 
described in Table 1.The average extra-systole in 24 hours in 
both groups was higher than 4.955 PC/day. Twelve patients 
had mitral valve prolapse without insufficiency (5 in group P 
and 7 in group MgP).
Quiz
Symptom Points Points
A - never - 0 point
B - once to 5 times/day - point
C - 6 to 20 times/day - 2 points
D - ≥ 21 times/day - 3 points
“Quality of Life” Score
Symptom Classification
I - Asymptomatic  - 0 point
II - Mid Symptomatic - 01 a 05 points
III - Moderate Symptomatic - 06 a 11 points
IV - Severe Symptomatic - more than 12 points
Failures or “leaps” in the chest
Couch with palpitation
Dizziness
Dyspnea
Sudoresis and/or chest pain
Total
Figure1 - This figure shows the score system to assess improvement of symptoms before and after the drugs in both groups (placebo and magnesium pidolate).
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Frequency of Premature Complexes 
In the MgP group, 76.6% of patients had a PCD reduction 
>70%, 10% of them >50% and only 13.4% <50%. In the 
P group, 40% showed slight improvement, <30%, in the PC 
frequency (Table 2/ Figure 2). Patients in the MgP group had an 
average reduction of 77.13% (SD = 24.57%) of PCD, whereas 
the placebo group had an average increase of 47.99% (SD = 
158.93%) in PCD (p<0.001) (Table 2/Figure 3). This difference 
was also consistent for both PVC and PsVC (p<0.001) (Table 
2). A few patients (13.4%) had only a slight improvement in 
PC density in the MgP group (<50% in PC frequency), but 
had improvement in symptoms.
Symptoms
In the P group, only 16.7% reported symptom improvement 
(score), whereas in the MgP group there was an improvement 
of 93.3% (p <0.001) (Table 2). As a categorical variable, 
there was improvement of symptoms in 93.3% of patients 
in the PMg, compared with only 13.3% in the placebo 
group (p <0.001) (Table 2). Figures 4 and 5 show the 
superiority of symptom improvement in patients receiving 
MgP compared with patients receiving P.  
Laboratory Findings
There were no significant changes in serum magnesium, 
potassium, sodium and calcium  during  the study in both 
groups. Serum magnesium did not differ significantly between 
groups (p = 0.743) or between periods of time (before and 
after oral supplementation; p = 0.154); moreover, serum 
potassium did not differ statistically between groups or during 
follow-up (p = 0.415, p = 0.804, respectively). Table 2 and 
Figure 6 illustrate the changes in magnesium.
Study Discontinuation and Adverse Events
Only one patient in the MgP group had to discontinue the 
protocol after 10 days due to diarrhea, which was promptly 
resolved within 24 hours. 
Discussion
Oral magnesium supplementation not only decreases 
the density of premature ventricular and supraventricular 
complexes, but also improves symptoms compared to placebo. 
In the placebo group, only 16.7% showed improvement in 
symptoms compared to 93.3% of patients using MgP.  Although 
most patients have improved PC density and symptoms, some 
patients have improved symptoms without a significant drop 
in PC density. The worsening of PCD in some patients in 
the placebo group can perhaps be explained by the great 
variability that involves spontaneous idiopathic arrhythmias. 
However, it is important to note that both groups were subjected 
to this variability, and even then, there was a statistically 
significant reduction of PCD in the magnesium group 
compared with the placebo group.
 The mechanisms by which magnesium administration 
reduces the incidence of PC are not entirely known. 
Magnesium is regarded as a significant regulator of cardiac cell 
function. Depletion of magnesium, as shown in some studies, 
may be proarrhythmic14. Zehender et al17 demonstrated that 
increased intake of potassium and magnesium in patients 
with frequent ventricular arrhythmias can result in a moderate but 
significant antiarrhythmic effect, although the frequency 
of tachyarrhythmia and symptoms has not been changed17. 
However, this sample differs from our results, probably because 
the population is different: most patients had other cardiac co 
morbidities, and some were using other medications.
          On the possibility of oral magnesium overload, it is 
important to note that patients in the MgP group had a normal 
Mg serum dosage during the 30-day follow-up, without major 
adverse effects or the need for suspension (except for a single 
patient with diarrhea). It is likely that intracellular levels of Mg 
are low, despite normal serum dosage, since serum dosage 
corresponds to only 0.3% of total magnesium. It would be 
interesting to find out minimally invasive, accurate methods 
to detect intracellular Mg levels18 to better understand many 
diseases, including cardiac arrhythmias.
 There are some studies with fluorescent markers 
specific to magnesium (and Mg-Fluo-4/AM KMG-20/AM)19, 
that aim at the cation dosage in various cell types, such as 
platelets, red blood cells, lymphocytes12, cardiomyocytes (in 
rats)19 and epithelial sublingual cells18. Silver et al18 showed 
a significant correlation between the magnesium values in 
heart muscle biopsies from bypass surgery, with the values 
measured in sublingual epithelial cell smear. Moreover, 
Table 1 - Baseline Characteristics of Study Patients
Characteristic MgP Placebo p value 
Gender Female, n (%) 17 (56,7%) 16 (53,3%) 0,795
Age (SD) # 46,47 ± 17,42 48,53 ± 13,18 0,606 
Valve Mitral Prolapses (SD) 07 (23,3%) 05 (16,7%) 0,519 
PCD* 256,41± 294,56 206,46 ± 249,89 0,496 
PVC density 129,31 ± 219,13 90,90 ± 157,72 0,639 
PsVC density 126,83 ±  225,82 115,55 ± 242,03 0,066 
Magnesium  2,05 ± 0,13 2,08 ± 0,14 0,439 
Potassium 4,20 ± 0,36 4,23 ± 0,36 0,690 
*Density of PC, PVC, PsVC: premature complexe per hour; # - Standard Deviation.
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Table 2 - Clinical Outcomes at 30 Days.
Variable PMg Placebo p
Improvement of PCD, n (%) < 0.001 
< 0% 0 (0.0%) 18 (60%)
0 to 30% 2 (6.7%) 12 (40%)
30 to 50% 2 (6.7%) 0 (0.0%)
50 to 70% 3 (10.0%) 0 (0.0%)
70% or more 23 (76.6%) 0 (0.0%)
Improvement of symptoms, n (%) < 0.001
No 2 (6.7%) 26 (86.7%)
Yes 28 (93.3%) 4 (13.3%)
Improvement of score, n (%) < 0.001
Less than 2 points 2 (6.7%) 25 (83.3%)
Two points or more 28 (93.3%) 5 (16.7%)
Reduction of PCD, % (SD) 77.13 ± 24.57 -47.99 ± 158.93 < 0.001
Reduction of PVC* 31.83 ± 280.62 -40.78 ± 187.34 < 0.001
Reduction of PsVC 22.64 ± 223.05 -212.78 ± 732.13 < 0.001
Magnesium (SD) 2.09 ± 0.10 2.09 ± 0.12 < 0.743
Potassium (SD) 4.17 ± 0.27 4.26 ± 0.29 < 0.415
*Density of PC, PVC, PsVC: premature complexe per hour.
Fig. 2 - Distribution of patients according to the percentage of improvement in the density of ventricular premature beats after 30 days in the placebo group (green) 
and magnesium pidolate (blue).
Percentage of improvement of density
Placebo Magnesium pidolate
0 to 30% 30 to 50% 50 to 70% 70% or more< 0
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Figure 4 - Percentage of patients who presented improvement of the symptoms: Yes (blue) or No (green), according to the group of treatment.
Figure 3 - Box-plot of the density of ventricular premature beats per time, before and after the treatment, according to each group: magnesium pidolate (blue) and 
placebo (green).
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Figure 5 - Percentage of patients who presented improvement in the score of symptoms. Smaller than 02 points (green) and greater than 02 points (blue).
Placebo Magnesium pidolate
Less than 2 points 2 points of more
Improvement of score
p < 0.001
 Figure 6 - Serum levels of magnesium before and on the 15th and 30th day of treatment with placebo (black line) and magnesium pidolate (red line).
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magnetic resonance imaging (MRI) is a noninvasive test for 
tissue Mg analysis. Recently, the Transient Receptor Potential 
Melastation channel and its role in hypomagnesemia were 
identified. Chronic Mg deficiency may be explained by 
changes in these specific membrane transporters12,20,21. 
Magnesium is closely related to the maintenance of cellular 
ionic balance in combination with sodium, potassium, and 
calcium; it cooperates with the Na +/K+ ATPase pump8,9,14. 
Magnesium deficiency causes an increase in intracellular 
Na +, which allows cellular K + loss9. Mg also affects calcium 
homeostasis, and many calcium channels are magnesium 
dependent. In addition, Mg is needed for the release and 
action of parathyroid hormone9.
Some conditions are associated with magnesium deficiency, 
such as metabolic syndrome22,23, hypertension, congestive 
heart failure, diabetes, preeclampsia, and arrhythmias14. A 
single study showed that 365 mg of magnesium per day for 
8 weeks lowers blood pressure24. According to Tong and 
Rude, magnesium reduces irregular heartbeat, and because 
intracellular Mg depletion may be present despite a normal 
serum Mg, magnesium deficiency must always be considered 
as a potential factor in cardiac dysrhythmias25. In the intensive 
care unit, magnesium is used when arrhythmias do not 
respond to conventional medications, and also in digitalis 
intoxication26. In heart failure, magnesium deficiency is 
caused by diuretic therapy, which increases the incidence of 
arrhythmia, among them premature complexes8,14.
The Mg balance among different compartments of the body 
occurs slowly, so that the concentration of Mg in one tissue 
does not correspond to that in another12. Less than 1% of total 
body Mg is present in blood9 and only 0.3% in serum11,12, so 
serum levels do not reflect the total body stores27,28. Therefore, 
even without changes in magnesium serum level, there was an 
improvement in arrhythmia with Mg replacement. It would be 
interesting to evaluate the nutritional value of Mg in food after 
processing (refining) and to establish the necessary amount of 
intake correlated with the values of intracellular Mg.
Although symptom improvement could be associated 
with a reduction in PC density, even in some cases in which 
this decline is not significant, symptoms also improved. 
This is partly explained by the placebo effect, as well as 
magnesium action in nerve cells.  A nutrition education rich in 
magnesium may be a practical alternative for the treatment of 
this arrhythmia. However, this information must be evaluated 
in another study. It is also important to control serum Mg during 
treatment and to assess renal function.
Limitations
Long-term follow-up was not performed; therefore, it is 
not possible to establish whether these patients are free from 
symptom recurrence after oral replacement of magnesium. 
Intracellular magnesium was not measured, but Mg serum 
dosages have shown that this replacement was safe and effective. 
The goal of reduction in the density of premature ventricular and 
supraventricular complexes and symptom improvement was 
achieved. The specific symptom score was not validated, because 
it does not exist in the literature. However, a simple categorical 
score was also made, with a good correlation between reduced 
PCD and symptom improvement. Moreover, the aim of this 
study was not to prevent life threatening arrhythmic events. It 
shows that the data should not be used as justification for treating 
patients with this objective, especially those with heart disease.
Conclusion
Simple oral Mg replacement reduced the density of 
premature ventricular and supraventricular complexes and 
specially  improved symptoms in our study population (no 
cardiac heart disease).Clinical and molecular studies are 
needed to evaluate intracellular Mg and develop better targets 
for the daily needs of this ion, show probable deficiencies, 
and explain how to prevent and better treat patients with 
symptomatic premature ventricular and supraventricular 
complexes and no apparent heart disease. 
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